Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
Stroke mortality and morbidity is expected to rise. Despite considerable recent advances within acute ischemic stroke treatment, scope remains for development of widely applicable neuroprotective agents. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally licensed for the management of Type 2 Diabetes Mellitus, have demonstrated pre-clinical neuroprotective efficacy in a range of neurodegenerative conditions. This systematic scoping review reports the pre-clinical basis of GLP-1RAs as neuroprotective agents in acute ischemic stroke and their translation into clinical trials. We included 35 pre-clinical studies, 11 retrospective database studies, 7 cardiovascular outcome trials and 4 prospective clinical studies. Pre-clinical neuroprotection was demonstrated in normoglycemic models when administration was delayed by up to 24 h following stroke induction. Outcomes included reduced infarct volume, apoptosis, oxidative stress and inflammation alongside increased neurogenesis, angiogenesis and cerebral blood flow. Improved neurological function and a trend towards increased survival were also reported. Cardiovascular outcomes trials reported a significant reduction in stroke incidence with semaglutide and dulaglutide. Retrospective database studies show a trend towards neuroprotection. Prospective interventional clinical trials are on-going, but initial indicators of safety and tolerability are favourable. Ultimately, we propose that repurposing GLP-1RAs is potentially advantageous but appropriately designed trials are needed to determine clinical efficacy and cost-effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Independently of these peripheral actions, GLP-1RAs show direct cerebral effects in animal stroke models, such as reduction of infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, blood–brain barrier permeability, and increased neurogenesis, neuroplasticity, angiogenesis, and brain perfusion.”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data accumulated from animal experiments conducted in acute ischemic stroke models with and without diabetes have also demonstrated a dose-dependent reduction of infarct volume in the brain by GLP-1RAs, when administered before or during the acute phase of ischemia at reperfusion or with some delay after the onset of reperfusion [60–62, 70].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Independently of these peripheral actions, GLP-1RAs show direct cerebral effects in animal stroke models, such as reduction of infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, blood–brain barrier permeability, and increased neurogenesis, neuroplasticity, angiogenesis, and brain perfusion.”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“Independently of these peripheral actions, GLP-1RAs show direct cerebral effects in animal stroke models, such as reduction of infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, blood–brain barrier permeability, and increased neurogenesis, neuroplasticity, angiogenesis, and brain perfusion.”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“Several animal studies have further shown that administration of GLP-1RAs, before or shortly after experimentally-induced stroke, increased angiogenesis, neurogenesis and cerebral blood flow (CBF), reduced neuroinflammation, oxidative stress, excitotoxicity, BBB leakage and apoptosis, and induced dose-dependent decreases in infarct volume [60–62].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [62]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,679
Goyal, M., Menon, B. K., van Zwam, W. H., Dippel, D. W. J., Mitchell, P. J., Demchuk, A. M., Dávalos, A., Majoie, C. B. L. M., van der Lugt, A., de Miquel, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00163-x · Cited by 7,815
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Feigin, V. L., Forouzanfar, M. H., Krishnamurthi, R., Mensah, G. A., Connor, M., Bennett, D. A., Moran, A. E., Sacco, R. L., Anderson, L., Truelsen, T., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61953-4 · Cited by 3,899
Emerging roles of caspase-3 in apoptosis
Porter, A. G., & Jänicke, R. U. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400476 · Cited by 3,855 · cited 1×
“Caspase proteins are also pro-apoptotic and increased levels are associated with higher rates of cell death.(54) Liraglutide, exendin-4, lixisenatide, rhGLP-1 and semaglutide have been shown to reduce levels of caspase-3 in pre-clinical models of stroke.”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Feigin, V. L., Norrving, B., & Mensah, G. A. (2017) · Circulation Research · doi:10.1161/circresaha.116.308413 · Cited by 2,184 · cited 1×
“5 million deaths per year globally and by 2030 will result in an annual loss of over 200 million disability-adjusted life years.(1,2) With an increasing number of strokes occurring in younger patients, alongside an increased number of stroke survivors, the cost of post-stroke care is rising.”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
1,026 Experimental treatments in acute stroke
O'Collins, V. E., Macleod, M. R., Donnan, G. A., Horky, L. L., van der Worp, B. H., & Howells, D. W. (2006) · Annals of Neurology · doi:10.1002/ana.20741 · Cited by 1,460
Thrombolysis for acute ischaemic stroke
Wardlaw, J. M., Murray, V., Berge, E., & del Zoppo, G. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000213.pub3 · Cited by 1,370 · cited 1×
“reduction in disability is highly time dependent.(4,5) Scope remains for further improvement, especially for patients who are unsuitable for reperfusion therapies or those within remote environments.”
BackgroundUpdate of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration
Chaitanya, G. V., Alexander, J. S., & Babu, P. P. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-31 · Cited by 926 · cited 2×
“Whilst controlled apoptosis is essential for the maintenance of homeostasis, dysregulated apoptosis, for example in within the ischemic penumbra, can result in increased cell death.(53) Bcl-2 is an antiapoptotic protein which functions at least in part by reducing cytochrome C release from the mitochondria.”
BackgroundDoing A Systematic Review: A Student’s Guide
Boland, A., Cherry, M. C., Dickson, R., & Carden, J. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.119 · Cited by 598
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“reported no significant change in body temperature when measured before and after treatment with exendin-4.(18) We did not identify any GLP-1RA study of AIS which varied temperature between groups.”
BackgroundCentral effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288 · cited 1×
“GLP-1 Receptor Agonists (GLP-1RAs), licensed for Type 2 Diabetes Mellitus (T2DM) have already demonstrated pre-clinical neuroprotective efficacy in Alzheimer’s Disease and clinical trials in neurodegenerative conditions are ongoing.(12,14) The aim of this systematic scoping review is to report the pre-clinical basis o…”
BackgroundBax-induced apoptotic cell death
Pawlowski, J., & Kraft, A. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.529 · Cited by 269 · cited 2×
“death.(52) Whilst controlled apoptosis is essential for the maintenance of homeostasis, dysregulated apoptosis, for example in within the ischemic penumbra, can result in increased cell death.”
BackgroundNeuroprotection for Ischaemic Stroke: Translation from the Bench to the Bedside
Sutherland, B. A., Minnerup, J., Balami, J. S., Arba, F., Buchan, A. M., & Kleinschnitz, C. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2012.00770.x · Cited by 259
Best, J. H., Hoogwerf, B. J., Herman, W. H., Pelletier, E. M., Smith, D. B., Wenten, M., & Hussein, M. A. (2011) · Diabetes Care · doi:10.2337/dc10-1393 · Cited by 251
Analysis of apoptosis by cytometry using TUNEL assay
Darzynkiewicz, Z., Galkowski, D., & Zhao, H. (2008) · Methods · doi:10.1016/j.ymeth.2007.11.008 · Cited by 247 · cited 1×
“TUNEL assays detect DNA degradation during the later stages of apoptosis and have demonstrated reduced apoptotic activity with liraglutide and exendin-4.(37,50,55) GLP-1RA administration following stroke induction has been associated with an anti-inflammatory effect.”
BackgroundThe clinical implications of ageing for rational drug therapy
Shi, S., Mörike, K., & Klotz, U. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0422-1 · Cited by 244 · cited 1×
“Stroke in humans occurs in the context of ageing, co-morbidity (hypertension, diabetes mellitus, atrial fibrillation, pre-existing cerebrovascular disease) and concomitant medication use.(8) Furthermore, factors such as gender, cerebral blood flow, body temperature and glycemic status may influence stroke mechanism an…”
BackgroundTeramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201
Neuroprotection in stroke: the importance of collaboration and reproducibility
Neuhaus, A. A., Couch, Y., Hadley, G., & Buchan, A. M. (2017) · Brain · doi:10.1093/brain/awx126 · Cited by 192 · cited 2×
“[6] Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.”
BackgroundPotential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191 · cited 2×
“GLP-1 Receptor Agonists (GLP-1RAs), licensed for Type 2 Diabetes Mellitus (T2DM) have already demonstrated pre-clinical neuroprotective efficacy in Alzheimer’s Disease and clinical trials in neurodegenerative conditions are ongoing.(12,14) The aim of this systematic scoping review is to report the pre-clinical basis o…”
BackgroundZhu, H., Zhang, Y., Shi, Z., Lu, D., Li, T., Ding, Y., Ruan, Y., & Xu, A. (2016) · Scientific Reports · doi:10.1038/srep26859 · Cited by 183
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Fei, Y., Tsoi, M.-F., & Cheung, B. M. Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0916-z · Cited by 156 · cited 1×
“99).(74) We acknowledge the limitations of this study.”
BackgroundMann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & The LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Circulation · doi:10.1161/circulationaha.118.036418 · Cited by 147
Effects of vascular endothelial growth factor in ischemic stroke
Ma, Y., Zechariah, A., Qu, Y., & Hermann, D. M. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23088 · Cited by 145 · cited 1×
“Vascular endothelial growth factor (VEGF) is known to promote angiogenesis and protect ischemic neurons from injury, demonstrating a crucial role in the neurovascular remodelling post-AIS.(58) Chen et al.”
BackgroundThe effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30423-1 · Cited by 137 · cited 1×
“Whilst dulaglutide reduced the incidence of ischemic stroke, it did not affect stroke severity.(60) Post-hoc analysis of CVOT trial data has identified sub-groups which may potentially derive greater cardiovascular protection.”
BackgroundAdult or Perinatal Brain Injury: Does Sex Matter?
Hurn, P. D., Vannucci, S. J., & Hagberg, H. (2005) · Stroke · doi:10.1161/01.str.0000153064.41332.f6 · Cited by 136
Darsalia, V., Mansouri, S., Ortsäter, H., Olverling, A., Nozadze, N., Kappe, C., Iverfeldt, K., Tracy, L. M., Grankvist, N., Sjöholm, Å., et al. (2012) · Clinical Science · doi:10.1042/cs20110374 · Cited by 130 · cited 4×
“A further four studies administered GLP-1RAs prior to and following stroke onset for between 0 and fourweeks – with dosing schedules of up to twice daily.(17,20,21,30) Most closely aligned with the proposed clinical application of administering treatment to GLP-1RA naı̈ve patients in the hyper-acute AIS setting, 17 st…”
BackgroundMethodInfluentialEstimating the number of UK stroke patients eligible for endovascular thrombectomy
McMeekin, P., White, P., James, M. A., Price, C. I., Flynn, D., & Ford, G. A. (2017) · European Stroke Journal · doi:10.1177/2396987317733343 · Cited by 129 · cited 1×
“Considerable advances have been made in acute ischemic stroke (AIS) treatment, notably reperfusion therapies, but these are limited to 10–20% of total stroke patients following careful clinical and radiological selection.(3) Even when intravenous thrombolysis and/or endovascular thrombectomy are administered, (1)Lanca…”
BackgroundSelf-citationThe Neurovascular Unit: Effects of Brain Insults During the Perinatal Period
Bell, A. H., Miller, S. L., Castillo-Melendez, M., & Malhotra, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01452 · Cited by 127 · cited 1×
“The neurovascular unit incorporates both cellular and extracellular components involved in the regulation of cerebral blood flow and blood-brain barrier function – it is involved with the maintenance of cerebral homeostasis and control of cerebral blood flow.(57) GLP-1RAs have been shown to increase cerebral blood flo…”
BackgroundNeuroprotective Effects of Liraglutide for Stroke Model of Rats
Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121513 · Cited by 120 · cited 1×
“demonstrated upregulation of VEGF in the cerebral cortex of liraglutide-treated, normoglycemic rats; however, this was not seen within the striatum.(32) Markers of neuronal, glial and endothelial function (NeuN, GFAP and vWF respectively) were used by Dong et al.”
MethodHyun Lee, C., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118
O’Brien, M. J., Karam, S. L., Wallia, A., Kang, R. H., Cooper, A. J., Lancki, N., Moran, M. R., Liss, D. T., Prospect, T. A., & Ackermann, R. T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6125 · Cited by 113 · cited 1×
“reported a retrospective cohort study of 132 737 insured adults with T2DM commenced on a second line diabetes medication between 2011 and 2015.(64) Adjusting for confounding variables, GLP-1RAs were associated with a reduction in stroke risk (HR 0.”
BackgroundBriyal, S., Shah, S. Z., & Gulati, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.064 · Cited by 109 · cited 2×
“Additional research is required to fully understand the role of cleaved GLP-1 subunits, including GLP-1 [28-36] and could go some way to explain the difference in stroke reduction between GLP-1RAs in CVOTs.”
BackgroundRaparelli, V., Elharram, M., Moura, C. S., Abrahamowicz, M., Bernatsky, S., Behlouli, H., & Pilote, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012940 · Cited by 106 · cited 1×
“reported an increased GLP-1RA associated reduction in cardiovascular risk in females compared to males.(69)”
Yang, X., Feng, P., Zhang, X., Li, D., Wang, R., Ji, C., Li, G., & Hölscher, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107748 · Cited by 103 · cited 5×
“Eight studies reported a reduction in poststroke neurological deficit when treated with liraglutide, six with exendin-4, two with rhGLP-1,(38,39) two with lixisenatide(41,42) and one study for each of PEx-4,(44) proGLP-1,(45) DMB,(46) OXM,(50) GLP-1/GIP DA,(47) P7C3(49) and semaglutide.(43) Nine studies reported a red…”
BackgroundMethodInfluentialDarsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103114 · Cited by 92 · cited 4×
“One study reported a non-statistically significant reduction in pro-inflammatory markers.(25) There is also deterioration in markers of oxidative stress following AIS.”
BackgroundResultInfluentialYang, J., Chen, W., Chen, Y.-P., Kuo, C.-Y., & Chen, S. (2016) · Theranostics · doi:10.7150/thno.15993 · Cited by 75 · cited 2×
“Additional research is required to fully understand the role of cleaved GLP-1 subunits, including GLP-1 [28-36] and could go some way to explain the difference in stroke reduction between GLP-1RAs in CVOTs.”
BackgroundDeng, C., Cao, J., Han, J., Li, J., Li, Z., Shi, N., & He, J. (2018) · Computational Intelligence and Neuroscience · doi:10.1155/2018/3094504 · Cited by 73
Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats
Briyal, S., Gulati, K., & Gulati, A. (2011) · Brain Research · doi:10.1016/j.brainres.2011.10.026 · Cited by 71
Svanström, H., Ueda, P., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30320-6 · Cited by 71 · cited 1×
“did not report this trend.(67,68) Raparelli et al.”
BackgroundLi, P.-C., Liu, L.-F., Jou, M.-J., & Wang, H.-K. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0272-9 · Cited by 69 · cited 4×
“Twelve studies administered exendin-4, nine used liraglutide, three used rhGLP-1 (recombinant human GLP-1), three used lixisenatide and one study each reported the utility of semaglutide,(43) PEx-4 (exendin-4 loaded poly-microspheres),(44) proGLP-1 (long acting GLP-1RA),(45) DMB (GLP-1R agonist/modulator),(46) dual GL…”
BackgroundInfluentialKuroki, T., Tanaka, R., Shimada, Y., Yamashiro, K., Ueno, Y., Shimura, H., Urabe, T., & Hattori, N. (2016) · Stroke · doi:10.1161/strokeaha.116.012934 · Cited by 60 · cited 3×
“demonstrated that hyperglycemia was associated with an increase in infarct volume, cerebral edema and hemorrhagic transformation in a mouse model that underwent transient, unilateral occlusion of the MCAO for 60min.(27) They reported that intraperitoneal administration of exendin-4 60min after stroke onset was associa…”
BackgroundResultKim, S., Jeong, J., Jung, H.-S., Kim, B., Kim, Y.-E., Lim, D.-S., Kim, S.-D., & Song, Y. S. (2017) · Experimental Neurobiology · doi:10.5607/en.2017.26.4.227 · Cited by 57
Paul, S. K., Klein, K., Maggs, D., & Best, J. H. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0178-3 · Cited by 55
Chen, F., Wang, W., Ding, H., Yang, Q., Dong, Q., & Cui, M. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0661-0 · Cited by 52
Zhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148827 · Cited by 50
Chien, C.-T., Jou, M.-J., Cheng, T.-Y., Yang, C.-H., Yu, T.-Y., & Li, P.-C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.126 · Cited by 46
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Gudbjörnsdottir, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 46
Han, L., Hölscher, C., Xue, G.-F., Li, G., & Li, D. (2016) · NeuroReport · doi:10.1097/wnr.0000000000000490 · Cited by 43
Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice
Zhang, H., Meng, J., Zhou, S., Liu, Y., Qu, D., Wang, L., Li, X., Wang, N., Luo, X., & Ma, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9854-1 · Cited by 43 · cited 5×
“Pragmatically, we therefore also included all retrospective database analyses of stroke incidence or composite cardiovascular outcomes in patients treated with GLP-1RAs.”
BackgroundInfluentialBarkas, F., Elisaf, M., & Milionis, H. (2019) · European Journal of Neurology · doi:10.1111/ene.13905 · Cited by 43 · cited 2×
“Meta-analysis by Barkas et al.(63) demonstrated a 13% reduction in the risk of total stroke associated with GLP-1RA treatment versus placebo (RR 0.”
MethodInfluentialHe, W., Wang, H., Zhao, C., Tian, X., Li, L., & Wang, H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29204 · Cited by 43 · cited 2×
“Additional research is required to fully understand the role of cleaved GLP-1 subunits, including GLP-1 [28-36] and could go some way to explain the difference in stroke reduction between GLP-1RAs in CVOTs.”
BackgroundAbdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. A. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1497-1 · Cited by 41
Gejl, M., Starup‐Linde, J., Thomsen, J. L. S., Gregersen, S., & Vestergaard, P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.096 · Cited by 39
Jia, Y., Gong, N., Li, T., Zhu, B., & Wang, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.008 · Cited by 38 · cited 1×
“A further four studies administered GLP-1RAs prior to and following stroke onset for between 0 and fourweeks – with dosing schedules of up to twice daily.(17,20,21,30) Most closely aligned with the proposed clinical application of administering treatment to GLP-1RA naı̈ve patients in the hyper-acute AIS setting, 17 st…”
BackgroundKang, Y. M., Cho, Y. K., Lee, J., Lee, S. E., Lee, W. J., Park, J.-Y., Kim, Y.-J., Jung, C. H., & Nauck, M. A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0070 · Cited by 36
Zeng, S.-S., Bai, J.-J., Jiang, H., Zhu, J.-J., Fu, C.-C., He, M.-Z., Zhu, J.-H., Chen, S.-Q., Li, P.-J., Fu, X.-Q., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00585 · Cited by 35
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 35 · cited 1×
“GLP-1 is produced in the brain and receptors are distributed throughout the central nervous system.(13) GLP-1 Receptor Agonists (GLP-1RAs), licensed for Type 2 Diabetes Mellitus (T2DM) have already demonstrated pre-clinical neuroprotective efficacy in Alzheimer’s Disease and clinical trials in neurodegenerative condit…”
BackgroundAnyanwagu, U., Mamza, J., Mehta, R., Donnelly, R., & Idris, I. (2016) · Heart · doi:10.1136/heartjnl-2015-309164 · Cited by 34
Li, Y., Wu, K.-J., Yu, S.-J., Tamargo, I. A., Wang, Y., & Greig, N. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.010 · Cited by 33
Chen, Y., Zhang, X., He, J., Xie, Y., & Yang, Y. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.12.015 · Cited by 32 · cited 3×
“demonstrated that intraperitoneal liraglutide therapy, administered 24 h following stroke induction and once daily for 14 days, was associated with increased VEGF expression when compared with normal saline treatment at days 7 and 14 post-AIS in a normoglycemic model.(35) Similarly, Sato et al.”
BackgroundMethodInfluentialPatorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12665 · Cited by 31
Protective effect of rhGLP-1 (7–36) on brain ischemia/reperfusion damage in diabetic rats
Zhao, L., Xu, J., Wang, Q., Qian, Z., Feng, W., Yin, X., & Fang, Y. (2015) · Brain Research · doi:10.1016/j.brainres.2015.01.014 · Cited by 30 · cited 1×
“Twelve studies reported an improvement in oxidative stress parameters following GLP-1RA administration in AIS – five studies of exendin-4,(19,24,26,27,50) four studies of liraglutide,(29,30,32,36) two of lixisenatide(41,42) and one of rhGLP.(40) Predominantly, studies reported reduced levels of malondialdehyde and inc…”
BackgroundDong, W., Miao, Y., Chen, A., Cheng, M., Ye, X., Song, F., & Zheng, G. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.045 · Cited by 29 · cited 11×
“In the animals treated with subcutaneous liraglutide, there was radiological evidence of increased glucose metabolism within the ischemic penumbra.(34)”
BackgroundInfluentialZimmerman, R. S., Hobbs, T. M., Wells, B. J., Kong, S. X., Kattan, M. W., Bouchard, J. R., Chagin, K. M., Yu, C., Sakurada, B., Milinovich, A., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12969 · Cited by 29
Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia
Zhang, H., Meng, J., Li, X., Zhou, S., Qu, D., Wang, N., Jia, M., Ma, X., & Xiaoxing, L. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.01.010 · Cited by 28 · cited 6×
“concluded that neuroprotection was not glucose dependent.(45) Yang et al.”
BackgroundInfluentialAbdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.045 · Cited by 28 · cited 1×
“However, whilst there are some reports of Ex-3-9 administration blocking neuroprotection,(21) suggestive of GLP-1R dependence, other studies did not demonstrated this trend, highlighting the possibility of a GLP-1R independent mechanism.(41,46) For example, GLP-1 is cleaved from endogenous GLP-1; research has shown th…”
BackgroundFilchenko, I., Simanenkova, A., Chefu, S., Kolpakova, M., & Vlasov, T. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118788079 · Cited by 28 · cited 3×
“reported that whilst reduction in neurological deficit was observed in the nondiabetic rat model treated with liraglutide, this trend was not observed in the diabetic groups.(31)”
BackgroundResultMuller, C., Cheung, N. W., Dewey, H. M., Churilov, L. P., Middleton, S., Thijs, V., Ekinci, E. I., Levi, C. R., Lindley, R. I., Donnan, G. A., et al. (2018) · International Journal of Stroke · doi:10.1177/1747493018784436 · Cited by 27
Exenatide in Acute Ischemic Stroke
Daly, S. C., Chemmanam, T., Loh, P.-S., Gilligan, A. K., Dear, A. E., Simpson, R. W., & Bladin, C. F. (2013) · International Journal of Stroke · doi:10.1111/ijs.12073 · Cited by 23 · cited 1×
“report the first pilot, non-randomised interventional study administering exenatide to eleven patients within 12 h of stroke onset followed by twice-daily injections until discharge.(70) Glucose levels were monitored, followed by a three-month modified Rankin score.”
MethodWang, Y.-H., Liou, K.-T., Tsai, K.-C., Liu, H.-K., Yang, L.-M., Chern, C.-M., & Shen, Y.-C. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.08.023 · Cited by 22 · cited 1×
“proliferation markers (ki67, BrdU) and neurodevelopmental markers (adam11, adamts20) alongside markers of increased neurogenesis (GSK-3 inhibition).(49) Darsalia et al.”
BackgroundFang, Y., Jiang, D., Wang, Y., Wang, Q., Lv, D., Liu, J., & Liu, C. (2018) · Drug Development Research · doi:10.1002/ddr.21439 · Cited by 21
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.10.003 · Cited by 21
Gad, S. N., Nofal, S., Raafat, E. M., & Ahmed, A. A. E. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01497-9 · Cited by 18 · cited 3×
“Reduced levels of other markers of inflammation, such as myeloperoxidase and interleukin, have also been reported.(30,37,51) One study reported a non-statistically significant reduction in pro-inflammatory markers.”
BackgroundTNF α in cerebral ischemia: another stroke against you?
Wilkins, H., & Swerdlow, R. H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13028 · Cited by 18 · cited 2×
“TNF-a is involved with the inflammatory response following stroke onset.(56) Five studies reported a reduction in TNF-a when compared to controls, three with lixisenatide(41,42,51) and one with each of liraglutide(37) and exendin-4.”
BackgroundResultNeuroprotective Effects of rhGLP‐1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury
Jiang, D., Wang, Y., Zang, Y., Liu, X., Zhao, L., Wang, Q., Liu, C., Feng, W., Yin, X., & Fang, Y. (2016) · Drug Development Research · doi:10.1002/ddr.21297 · Cited by 17 · cited 2×
“reported that stroke infarct volume in the rhGLP-1 group was significantly reduced when compared to insulin treatment.(38) Metformin was also shown to ameliorate hyperglycemia but did not confer the additional neuroprotective outcomes associated with liraglutide.”
BackgroundResultMcGrath, R. T., HOCKING, S. L., Priglinger, M. L., Day, S., Herkes, G., Krause, M., & Fulcher, G. R. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008203 · Cited by 14
Frison, V., Simioni, N., Marangoni, A., Balzano, S., Vinci, C., Zenari, L., De Moliner, L., Tadiotto, F., D’Ambrosio, M., Confortin, L., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0503-4 · Cited by 12
GLP-1(28-36)amide, a Long Ignored Peptide Revisited
Huang, K., Zhou, B., Ji, K., Peng, A., & Yang, X. (2014) · The Open Biochemistry Journal · doi:10.2174/1874091x01408010107 · Cited by 11 · cited 1×
“nonapeptide to have antioxidant, anti-apoptotic and mitochondrial regulatory properties in pancreatic cells – further research is required to establish its role in neural tissue.(59) The reduction in apoptosis, oxidative stress and inflammation, alongside increased neurogenesis, angiogenesis and cerebral blood flow is…”
BackgroundPrehospital exenatide in hyperglycemic stroke—A randomized trial
Larsson, M., Castrén, M. K., Lindström, V., von Euler, M., Patrone, C., Wahlgren, N. G., & Nathanson, D. (2019) · Acta Neurologica Scandinavica · doi:10.1111/ane.13166 · Cited by 9 · cited 1×
“report on PROLOGUES, a randomised controlled trial comparing pre-hospital administration of exenatide with standard care for hyperglycemia in patients with suspected stroke.(71) Nineteen patients were randomised, of an intended forty two, with eight of them receiving exenatide.”
Background
Research works printed but not linked: 3
- Zhu H, 2016, Sci Rep, 6
- Kang YM, 2018, Diabetes Metab J, 42
- Barkas F, Eur J Neurol
Cited by
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Hölscher, C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15508 · Cited by 145
“For further details on this topic, please consult the reviews (Darsalia et al., 2018; Erbil et al., 2019; Groeneveld et al., 2016; Maskery et al., 2021).”
BackgroundInsulin resistance in ischemic stroke: Mechanisms and therapeutic approaches
Ding, P.-F., Zhang, H., Wang, J., Gao, Y., Mao, J.-N., Hang, C., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1092431 · Cited by 161
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
“Augmented blood flow and/or vascular anti-inflammatory actions also reduce infarct volume and improve functional outcome (for review, see (Basalay et al., 2020; Maskery et al., 2021).”
BackgroundStrain, W. D., Frenkel, O., James, M. A., Leiter, L. A., Rasmussen, S., Rothwell, P. M., Sejersten Ripa, M., Truelsen, T. C., & Husain, M. (2022) · Stroke · doi:10.1161/strokeaha.121.037775 · Cited by 93
“30 GLP-1 RAs improve neuronal survival, reducing infarct size by up to 75% in rat models of transient middle cerebral artery occlusion.”
BackgroundInfluentialSelf-citationGoldenberg, R. M., Cheng, A. Y. Y., Fitzpatrick, T., Gilbert, J. D., Verma, S., & Hopyan, J. J. (2022) · Stroke · doi:10.1161/strokeaha.121.038151 · Cited by 82
Metadata
- Authors
- Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C.
- Affiliations
- Royal Preston Hospital (GB)
- Research and Experimental Center, Henan University of Chinese Medicine, Zhengzhou, Henan Province, China
- University of Lancashire (GB)
- Newcastle University (GB)
- University of Exeter (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Maskery, Mark P
- ORCID
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2020-09-20
- Volume
- 41
- Issue
- 1
- Pages
- 14-30
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- PMC
- PMC7747170
- OpenAlex
- W3087075091
- Cited by
- 51
- References
- 89
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 8 · 2020: 1
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cerebral Blood Flow & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (acceptedVersion)
- CLOK (University of Central Lancashire) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institute for Health and Care Research (NF-SI-0515-10116, ACF-2017-05-001)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- GLP-1 receptor agonists, ischemic stroke, neuroprotection, drug repurposing, semaglutide, dulaglutide, infarct size, oxidative stress, neuroinflammation, neurogenesis, angiogenesis, cerebral blood flow, stroke incidence, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Ischemic Stroke, Animals, Disease Models, Animal, Humans, Prospective Studies, Retrospective Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.